Generic placeholder image

Current Analytical Chemistry

Author(s): Ibrahim A. Darwish*, Nasr Y. Khalil and Mohammad AlZeer

DOI: 10.2174/1573411016999200802024151

DownloadDownload PDF Flyer Cite As
ICH/FDA Guidelines-Compliant Validated Stability-Indicating HPLC-UV Method for the Determination of Axitinib in Bulk and Dosage Forms

Page: [1106 - 1112] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Axitinib (AXT) is a member of the new generation of the kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. Its therapeutic benefits depend on assuring the good-quality of its dosage forms in terms of content and stability of the pharmaceutically active ingredient.

Objective: This study was devoted to the development of a simple, sensitive and accurate stabilityindicating high-performance liquid chromatographic method with ultraviolet detection (HPLC-UV) for the determination of AXT in its bulk and dosage forms.

Methods: Waters HPLC system was used. The chromatographic separation of AXT, internal standard (olaparib), and degradation products were performed on the Nucleosil CN column (250 × 4.6 mm, 5 μm). The mobile phase consisted of water:acetonitrile:methanol (40:40:20, v/v/v) with a flow rate of 1 ml/min, and the UV detector was set at 225 nm. AXT was subjected to different accelerated stress conditions and the degradation products, when any, were completely resolved from the intact AXT.

Results: The method was linear (r = 0.9998) in the concentration range of 5-50 μg/ml. The limits of detection and quantitation were 0.85 and 2.57 μg/ml, respectively. The accuracy of the method, measured as recovery, was in the range of 98.0-103.6% with relative standard deviations in the range of 0.06-3.43%. The results of stability testing revealed that AXT was mostly stable in neutral and oxidative conditions; however, it was unstable in alkaline and acidic conditions. The kinetics of degradation were studied, and the kinetic rate constants were determined. The proposed method was successfully applied for the determination of AXT in bulk drug and dosage forms.

Conclusion: A stability-indicating HPLC-UV method was developed and validated for assessing AXT stability in its bulk and dosage forms. The method met the regulatory requirements of the International Conference on Harmonization (ICH) and the Food and Drug Administration (FDA). The results demonstrated that the method would have great value when applied in quality control and stability studies for AXT.

Keywords: Axitinib, HPLC, kinase inhibitor, renal cell carcinoma, stability-indicating method, ultraviolet detection.

Graphical Abstract

[1]
Grünwald, V.; Merseburger, A.S. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. OncoTargets Ther., 2012, 5, 111-117.
[http://dx.doi.org/10.2147/OTT.S23273] [PMID: 22787405]
[2]
Gross-Goupil, M.; François, L.; Quivy, A.; Ravaud, A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin. Med. Insights Oncol., 2013, 7, 269-277.
[http://dx.doi.org/10.4137/CMO.S10594] [PMID: 24250243]
[3]
Rini, B.I.; Wilding, G.; Hudes, G.; Stadler, W.M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P.C.; Wood, L.; Dutcher, J.P. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27(27), 4462-4468.
[http://dx.doi.org/10.1200/JCO.2008.21.7034] [PMID: 19652060]
[4]
Hu-Lowe, D.D.; Zou, H.Y.; Grazzini, M.L.; Hallin, M.E.; Wickman, G.R.; Amundson, K.; Chen, J.H.; Rewolinski, D.A.; Yamazaki, S.; Wu, E.Y.; McTigue, M.A.; Murray, B.W.; Kania, R.S.; O’Connor, P.; Shalinsky, D.R.; Bender, S.L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14(22), 7272-7283.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0652] [PMID: 19010843]
[5]
McTigue, M.; Murray, B.W.; Chen, J.H.; Deng, Y.L.; Solowiej, J.; Kania, R.S. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc. Natl. Acad. Sci. USA, 2012, 109(45), 18281-18289.
[http://dx.doi.org/10.1073/pnas.1207759109] [PMID: 22988103]
[6]
Inlyta (axitinib) tablets Label-FDA . https://www.accessdata.fda. gov/drugsatfda_docs/label/2012/202324lbl.pdf
[7]
Ahuja, S.; Alsante, K.M. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals; Academic Press: San Diego, 2003.
[8]
Ahuja, S. Impurities Evaluation of Pharmaceuticals; Marcel Dekker Inc.: New York, 1998.
[9]
FDA. . Guidance for Industry: Impurities in Drug Product, Draft guidance, Center for Drug Evaluation and Research; CDER, 1998.
[10]
ICH. Harmonized Tripartite Guideline . Stability Testing of New Drug Substances and Products Q1A (R2). International Conference on Harmonization, IFPMA, Geneva, , 2003.
[11]
Harmonized Tripartite Guideline, I.C.H. 2005.
[12]
, 1995.
[13]
Donald, D. Hong, D.D.; Shah,M. Development and Validation of HPLC Stability-Indicating Assays.Drug Stability, Principles and Practices; Carstensen, J.T; Rhodes, C.T., Ed.; Marcel Dekker Inc.: New York, 2002, p. 520.
[14]
Khan, H.; Ali, M.; Ahuja, A.; Ali, J. Stability testing of pharmaceutical products-comparison of stability testing guidelines. Curr. Pharm. Anal., 2010, 6, 142-150.
[http://dx.doi.org/10.2174/157341210791202627]
[15]
Illendula, S.; Sree, A.N.; Ganesh, Ch.; Sneha, K.; Sravya, M.; Sayujya, B.; Sandhya, P.; Shirisha, V.; Rao, K.N.V.; Dutt, K.R. Method development and validation of axitinib in bulk and pharmaceutical dosage form by UV-spectroscopic method. Indo Am. J. Pharm. Sci., 2019, 06(03), 6221-6227.
[16]
Ranjeetha, M.; Niranjan, M.S.; Chaluvaraju, K.C.; Mamatha, M.; Darshitha, R.; Varsha, C. A New derivative spectroscopic method for the estimation of axitinib and everolimus in bulk and physical mixture. J. Chem. Pharm. Res., 2018, 10(5), 61-66.
[17]
Rathod, R.H.; Patil, A.S.; Shirkhedkar, A.A. Development and validation of zero and first order derivative area under curve spectrophotometric methods for the determination of axitinib in bulk material and in-house tablets. Res. Pharm., 2017, 1(2), 32-36.
[18]
Pal, N.; Mahtab, T.; Saleem, S.; Tabasum, S.; Rao, A.S. HPLC method development and validation for the determination of axitinib in tablet dosage form. Eur. J. Biomed. Pharm. Sci., 2019, 6(8), 337-344.
[19]
Panda, S.; Bera, V.; Panda, N. Development and validation of a superior high performance liquid chromatographic method for quantification of axitinib in solid oral dosage form. Am. J. Mod. Chromatogr., 2016, 2016, 1003.
[http://dx.doi.org/10.7726/ajmc.2016.1003]
[20]
Chalikwar, S.S.; Kayande, S.D.; Singh, I.; Shirkhedkar, A.A. Exploring RP-HPLC method for analysis of axitinib in bulk and in house tablets. J. Pharm. Technol. Res. Mang., 2018, 6(2), 135-141.
[21]
Yabré, M.; Ferey, L.; Somé, I.T.; Gaudin, K. Greening reversed phase liquid chromatography methods using alternative solvents for pharmaceutical analysis. Molecules, 2018, 23(5), 1-25.
[http://dx.doi.org/10.3390/molecules23051065] [PMID: 29724076]
[22]
Sunil, M.; Ramanjaneyulu, A.; Harshavardhan, A.; Raj, P.S. Bai, N.M.; Aswani, T. Determination, Development and validation of method for simultaneous axitinib pharmaceutical dosage form by a reverse phase HPLC. Res. & Rev. Drugs & Drugs Dev., 2019, 1(2), 28-42.
[23]
Ashok, G.; Sumanta, M. Development and validation of stability indicating method for the estimation of axitinib in tablet dosage forms by UPLC. Asian J. Pharm. Biol. Res., 2017, 5(3), 1-6.
[http://dx.doi.org/10.30750/ijpbr.5.3.1]
[24]
Reddy, B.J.Ch.; Sarada, N.C. Development and validation of stability indicating RP-HPLC method for the determination of axitinib in bulk and its pharmaceutical formulations. Der Pharm. Lett., 2016, 8(11), 97-106.
[25]
Martin, A.; Swarbrick, J.; Cammarata, A.; Chun, A. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, 3rd ed; Lea & Febiger: Philadelphia, 2004, p. 371.